Coherus BioSciences Forges Key Oncology Alliance with Janssen
Published on 02/06/2026 at 20:35 | Redaktion boerse-global.de
Coherus BioSciences has secured a significant partnership for its clinical development efforts, aligning with Janssen Research & Development, a Johnson & Johnson company. The collaboration will evaluate a promising oncology candidate for metastatic castration-resistant prostate cancer (mCRPC), marking a strategic step for the biopharmaceutical firm. This move arrives as the company’s shares show considerable strength in the early part of the trading year.
The alliance centers on a Phase 1b combination study. Coherus’s investigational anti-CCR8 antibody, Tagmokitug (CHS-114), will be tested alongside Janssen’s therapeutic agent, Pasritamig. A critical feature of the agreement is its structure: Coherus will act as the study sponsor, while Janssen will supply Pasritamig.
For Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
